Ruth O'Regan, MD
There are several genomic assays and corresponding data sets that physicians can use to assess the risk of recurrence for a patient with early-stage hormone receptor (HR)–positive, HER2-negative breast cancer and their need for chemotherapy or endocrine therapy alone.
However, because a lot of these data fall short in terms of extended endocrine therapy and patients with node-positive disease, physicians should err on the side of caution when it comes to higher-risk patients until those results read out, explained Ruth O’Regan, MD.
“The use of genomic subtyping in early-stage estrogen receptor (ER)–positive breast cancer has really allowed us to make much more robust decisions for our patients. We've made huge strides in avoiding chemotherapy for patients with early-stage ER-positive breast cancer,” said O’Regan. “The remaining questions are, ‘How do we manage patients with node-positive disease? For premenopausal patients, can we get away with ovarian suppression rather than chemotherapy? Who are the patients who need longer durations of endocrine therapy?’”
... to read the full story